Kazia Therapeutics Stock (NASDAQ:KZIA)
Previous Close
$1.41
52W Range
$1.32 - $15.80
50D Avg
$3.31
200D Avg
$3.68
Market Cap
$4.59M
Avg Vol (3M)
$100.57K
Beta
2.08
Div Yield
-
KZIA Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HCWB | HCW Biologics Inc. |
| OCUL | Ocular Therapeutix, Inc. |
| MNOV | MediciNova, Inc. |
| MREO | Mereo BioPharma Group plc |
| SLS | SELLAS Life Sciences Group, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| QSI | Quantum-Si incorporated |
| CADL | Candel Therapeutics, Inc. |
| SEER | Seer, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| ACHL | Achilles Therapeutics plc |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| OKYO | OKYO Pharma Limited |
| KTTA | Pasithea Therapeutics Corp. |
| NLSP | NLS Pharmaceutics AG |
| RNXT | RenovoRx, Inc. |